# InterAACT 2 (NCT04472429)

> Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

No report yet. It can be ordered.

- Drugs tested: retifanlimab
- Indication: locally recurrent or metastatic squamous cell anal carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04472429
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Incyte Corporation
- Conditions: Squamous Cell Carcinoma of the Anal Canal
- Interventions: carboplatin; paclitaxel; retifanlimab
- Enrollment: 308
- Primary outcome: Progression-free Survival (PFS)

## Indexed commentary on InterAACT 2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 21 posts on X
- 5 YouTube videos
- 5 podcast episodes
- 1 video on X

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=interaact-2-nct04472429

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04472429", "email": "<work email>"}; the inbox owner confirms by the emailed link.